Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan PK in Pediatric Migraine
NCT03988088Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of lasmiditan in migraine (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Drug Concentration at 24 hours and Area Under the Concentration-Versus-Time Curve at 24 hours. Started Jul 2019; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03988088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988088.